

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 30, 2020**

---



**GENOCEA BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-36289**  
(Commission File Number)

**51-0596811**  
(IRS Employer  
Identification No.)

**Cambridge Discovery Park  
100 Acorn Park Drive, 5th Floor  
Cambridge, MA 02140**

(Address of principal executive offices, including zip code)  
(Registrant's telephone number, including area code): **(617) 876-8191**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, \$0.001 par value per share	GNCA	NASDAQ Capital Market

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 2.02 Results of Operations and Financial Condition.**

On April 30, 2020, Genocea Biosciences, Inc. (the "Company") announced its financial results for the first quarter ended March 31, 2020. A full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 [Press Release issued by Genocea Biosciences, Inc. on April 30, 2020](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GENOCEA BIOSCIENCES, INC.**

By: /s/ DIANTHA DUVALL

Diantha Duvall

Chief Financial Officer

*(Principal Financial Officer)*

Date: April 30, 2020



**Investor Contact:**

Dan Ferry  
617-430-7576  
daniel@lifesciadvisors.com

**Genocea Provides First Quarter 2020 Corporate Update**

***Clinical stage programs GEN-009 and GEN-011 continue to advance***  
***Anticipate GEN-011 IND filing in Q2***  
***Expect GEN-009 Phase 1/2a Part B readout in Q3***  
***GEN-011 Virtual Symposium planned for May 12<sup>th</sup>***

***Conference call today at 8:30 a.m. EDT***

**CAMBRIDGE, Mass., April 30, 2020** - [Genocea Biosciences, Inc.](#) (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today reported its operating and financial results for the first quarter ended March 31, 2020.

Genocea remains on track with its two differentiated clinical stage programs - GEN-009 (neoantigen vaccine) and GEN-011 (neoantigen cell therapy). The GEN-009 phase 1/2a clinical trial has reached sufficient enrollment for Part B of the study, which evaluates GEN-009 in combination with standard-of-care ICI therapy. The company anticipates preliminary clinical results in Q3 2020. Genocea also intends to file an Investigational New Drug Application (IND) for GEN-011 later this quarter with preliminary clinical results expected in 1H 2021.

Genocea will host a GEN-011 virtual symposium on May 12<sup>th</sup> at 12 p.m. EDT with Eric Tran, PhD, who generated transformational data showing the potential of TIL therapy as a National Cancer Institute (NCI) fellow. Dr. Tran will provide a brief overview of the current T cell therapy landscape - including the evolution of adoptive cell therapy and the need for new approaches to improve patient outcomes. Genocea will provide an in-depth profile of GEN-011 - a potential best-in-class adoptive T cell therapy -targeting an unprecedented breadth of relevant neoantigens, avoiding unwanted expansion of deleterious T cells and employing peripheral blood in a rapidly scalable manufacturing process to treat large cancer patient populations.

"Over the last quarter, we have conducted our GEN-009 clinical program and prepared GEN-011 for IND filing as planned," said Chip Clark, President and Chief Executive Officer, Genocea. "We remain focused on the opportunity to create life-changing medicines for cancer patients during these uncertain and challenging times."

**First Quarter 2020 Financial Results**

- Cash position: As of March 31, 2020, cash and cash equivalents were \$26.5 million versus \$40.1 million as of December 31, 2019.
  - Research and Development (R&D) expenses: R&D expenses were \$10.0 million for the quarter ended March 31, 2020, compared to \$6.5 million for the same period in 2019.
  - General and Administrative (G&A) expenses: G&A expenses were \$3.4 million for the quarter ended March 31, 2020, compared to \$3.0 million for the same period in 2019.
  - Net loss: Net loss was \$12.9 million for the quarter ended March 31, 2020, compared to \$15.6 million for the same period in 2019.
-

**Guidance**

Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2021.

**Conference Call**

Genocea will host a conference call and webcast today at 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 4855738. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at <https://ir.genocea.com/events-and-presentations>. A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

**About Genocea Biosciences, Inc.**

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and expect preliminary clinical results in the third quarter of 2020, and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood, for which we intend to file an Investigational New Drug Application in the second quarter of 2020. To learn more, please visit [www.genocea.com](http://www.genocea.com).

**Forward-Looking Statements**

*This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.*

**(Tables to follow)**

---

**GENOCEA BIOSCIENCES, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)**  
(In thousands)

	March 31, 2020	December 31, 2019
Cash and cash equivalents	\$ 26,509	\$ 40,127
Other assets	18,683	12,484
<b>Total assets</b>	<b>\$ 45,192</b>	<b>\$ 52,611</b>
Debt, current and long-term	\$ 13,515	\$ 13,407
Accounts payable, accrued expenses and other liabilities	16,959	11,676
Warrant liability	1,705	2,486
<b>Total liabilities</b>	<b>32,179</b>	<b>27,569</b>
Stockholders' equity	13,013	25,042
<b>Total liabilities and stockholders' equity</b>	<b>\$ 45,192</b>	<b>\$ 52,611</b>

**GENOCEA BIOSCIENCES, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)**  
(In thousands, except per share data)

	Three Months Ended March 31,	
	2020	2019
Operating expenses:		
Research and development	\$ 9,987	\$ 6,460
General and administrative	3,388	3,017
<b>Total operating expenses</b>	<b>13,375</b>	<b>9,477</b>
Loss from operations	(13,375)	(9,477)
Other income (expense)	522	(6,090)
<b>Net loss</b>	<b>\$ (12,853)</b>	<b>\$ (15,567)</b>
Net loss per share - basic and diluted	\$ (0.46)	\$ (1.22)
Weighted-average number of common shares used in computing net loss per share	28,141	12,713